Receive funding for your R&D Projects!
Your partner for subsidy advice
Your partner for subsidy advice
The antibody of this invention is a mouse monoclonal antibody directed against SUMO176-86 recognizing SUMO1 of human, mouse, chicken and X. laevis. It is suitable for western blot and immune precipitation as well as for large-scale enrichment of SUMOylated species by IP / peptide elution.
The invention reveals a method, based on metylation analysis of intragenic regions of the gene DGKA, for estimating the risk of developing radiation induced fibrosis and can therefore be used for therapy planning.
The invention discloses a device that enables bead purification and mixing of the sample without the need for moving the reaction plate from one deck position to the other and hence saving time and deck space.
The Mastomys mouse model is the only existing natural laboratory model to investigate PV pathogenesis and tumor development in the skin, ear, eye and tongue and could help to develop prophylactic or therapeutic approaches to prevent those lesions.
The invention shows that a combination of HDAC and ALK inhibitors for tumortherapy is surprisingly synergistic and can additionally overcome single substance drug resistance.
The present invention comprises the use of two serum/plasma markers for stage discrimination and prediction of survival as well as treatment response in breast cancer patients. Test statistics show that these markers outperform established ones like the number of circulating tumor cells (CTCs).